For example, an Alk inhibitor in combination with a VEGF inhibitor and a cell-based therapy may be more suitable approach for a “cold” MYCN-A tumor exhibiting an Alk mutation and a dysfunctional vasculature. Here, VEGFA is linked to neoplasm.